The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Patients with extensive disease(ED) small cell lung cancer is still have a dismal prognosis,
even though the first line chemotherapy showing about 70% response rate. Most of the patients
will relapse with in 6 months after the chemotherapy and the following therapy such as second
line chemotherapy have a very limited efficacy to these patients. Currently, there is no
standard 3rd line therapy for the patients with ED small cell lung cancer(SCLC).
As the investigators know, Nab-paclitaxel had showing promising efficacy in several cases
report in the patients with SCLC, the aim of this clinical trial is to investigate the
efficacy and safety of nab-paclitaxel as a single agent in the SCLC patients with extensive
disease and failed to first line/ second line chemotherapy.